- Will AI disrupt the payments industry in 2026? Izak van Heerden, Senior Manager: Development at Altron FinTech
- African Banks and Institutions must Lead on Urbanisation Finance – or Risk being Sidelined by Foreign Investors, says Pan-African banker
- How to Survive When Your Business Hits a Wall
- Driving business efficiency across the fintech ecosystem
- Accion Announces Close of $61.6M Second Accion Venture Lab Fund Investing in Early-Stage Inclusive Fintech
Big Pharma Looks Beyond Covid With AstraZeneca Eyeing Gilead
NEW YORK (Capital Markets in Africa) — Two drugmakers behind the industry’s most prominent responses to the Covid-19 pandemic are looking into the possibility of a combined future as economies emerge from lockdowns. AstraZeneca Plc, co-developer of one of the fastest-moving experimental coronavirus vaccines, has made a preliminary approach to Gilead Sciences Inc., maker of the only U.S.-approved treatment, according to people familiar with the matter. If they decided to pursue a merger, it would be…
Read More







